Christine e. Seidman - Genetic Mutations

Author Information

Christine E. Seidman is a prominent geneticist affiliated with the Department of Genetics at Harvard Medical School in Boston, MA, USA. Her research primarily focuses on genetic determinants and mechanisms underlying various forms of heart disease. Her affiliation at one of the world's leading medical schools underscores her significant contributions to the field of genetics and cardiovascular research.

Research Contributions

Christine E. Seidman has made substantial contributions to the understanding of genetic factors involved in cardiovascular diseases. Her recent research includes exploring cell cycle defects in childhood-onset cardiomyopathy associated with Noonan syndrome, the impact of mitochondrial DNA variation on congenital heart disease risk, and the genetic underpinnings of hypertrophic cardiomyopathy. Her work also delves into the genetic aspects of cancer therapy-associated cardiotoxicity and the engineering of cardiac tissue models. Her extensive research portfolio reflects a deep commitment to elucidating the genetic mechanisms that contribute to heart disease and developing innovative approaches to treatment and prevention.

Aliases

Christine E. Seidman is also known by several aliases in academic publications, including C Seidman, Christine E. Seidman, Christine E. Seidman, C. E. Seidman, C E Seidman, and Christine Seidman.

Publication and Citation Metrics

Metric	Value
Total Citation Count	84,124
h-index	147
Total Number of Papers	706

Publications:

Cell cycle defects underlie childhood-onset cardiomyopathy associated with Noonan syndrome

DOI: 10.1016/j.isci.2021.103596

Year: 2022

Neither cardiac mitochondrial DNA variation or copy number contribute to congenital heart disease risk.

DOI: 10.1016/j.ajhg.2022.03.011

Year: 2022

Alterations of sarcomeric stoichiometry by nonsense mediated decay of MYBPC3-mRNA in hypertrophic cardiomyopathy patients with truncation mutations

DOI: 10.1016/j.bpj.2021.11.599

Year: 2022

Genome-Wide De Novo Variants in Congenital Heart Disease Are Not Associated With Maternal Diabetes or Obesity

DOI: 10.1161/CIRCGEN.121.003500

Year: 2022

Transcription factor protein interactomes reveal genetic determinants in heart disease

DOI: 10.1016/j.cell.2022.01.021

Year: 2022

Genetics of cancer therapy-associated cardiotoxicity.

DOI: 10.1016/j.yjmcc.2022.03.010

Year: 2022

Engineering a living cardiac pump on a chip using high-precision fabrication.

DOI: 10.1126/sciadv.abm3791

Year: 2022

Plakophilin-2 truncating variants impair cardiac contractility by disrupting sarcomere stability and organization

DOI: 10.1126/sciadv.abh3995

Year: 2021

Genetic and Phenotypic Landscape of Peripartum Cardiomyopathy

DOI: 10.1161/CIRCULATIONAHA.120.052395

Year: 2021

Abstract 402: Defining Diverse Disease Pathomechanisms Across Thick And Thin Filament Hypertrophic Cardiomyopathy Variants.

DOI: 10.1161/res.129.suppl_1.402

Year: 2021

What is Molecular Biology?

What are the sources of PAH exposure?

What is the Future of Hemoglobin Electrophoresis?

How Can Genetic Mutations Be Treated or Managed?

How Do Point Mutations Occur?

What Are the Potential Consequences of Radiation-Induced Mutations?

Are There Limitations to Hemoglobin Electrophoresis?

How are Neurodevelopmental Disorders Linked to Genetics?

What Ethical Considerations are Associated with Biotechnology in Genetics?

How Does Gene Therapy Work?

Partnered Content Networks

Relevant Topics